GlassScriptPhysician profile
Amesh A Adalja
NPI 1023209871
$415,216.10
in general payments reported to CMS, 2019-2025
17 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $36K · 2021: $12K · 2022: $37K · 2023: $141K · 2024: $59K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Consulting Fee: $51K · Travel and Lodging: $27K · Food and Beverage: $6,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,196.00 |
| Consulting Fee | $51,226.25 |
| Travel and Lodging | $26,728.75 |
| Food and Beverage | $6,632.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $157,057.44 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $150,217.81 | 2019-2025 | Zerbaxa, Prevymis |
| Sanofi Pasteur INC. | $17,646.94 | 2021-2024 | |
| Shionogi INC | $15,751.64 | 2022-2025 | Fetroja, S-217622 |
| Pfizer INC. | $13,866.11 | 2022-2024 | |
| Emergent Biosolutions INC. | $12,350.00 | 2020-2025 | |
| Henry Schein, INC. | $12,300.00 | 2020-2022 | |
| Becton, Dickinson and Company | $7,029.79 | 2023-2025 | |
| Invivyd INC | $6,715.60 | 2025 | Pemgarda |
| Seqirus USA INC | $6,028.66 | 2022-2024 | |
| Modernatx, INC. | $5,690.30 | 2025 | Mresvia |
| Siemens Medical Solutions USA, INC. | $3,000.00 | 2022 | |
| Biomerieux INC | $2,982.52 | 2025 | Biofire Spotfire Respiratory (R) Panel |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2021 | |
| Melinta Therapeutics, LLC | $1,032.79 | 2022-2025 | Kimyrsa, Rezzayo, Vabomere |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $910.00 | 2024 | |
| Abbvie INC. | $616.50 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amesh Adalja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.